Inovio's INO-3107 Nears Oct. 30 FDA Decision for Recurrent Respiratory Papillomatosis
核心洞察
Inovio Pharmaceuticals is awaiting an Oct. 30 FDA target action date for INO-3107, an investigational DNA medicine for HPV 6- and HPV 11-associated recurrent respiratory papillomatosis (搜索).
In the Phase I/II RRP-001 study, 72% of patients had a 50% to 100% surgery reduction in year one, rising to 86% in year two.
The BLA was filed under accelerated approval, but the FDA's file acceptance letter preliminarily questioned eligibility because an RRP product already holds full approval.
Inovio Pharmaceuticals is in the late stages of the regulatory review of INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis (搜索) (RRP), with a U.S. Food and Drug Administration target action date of Oct. 30. President and CEO Jacqueline Shea outlined the program's status during a Cantor Fitzgerald fireside chat, describing a biologics license application (BLA) filed under the FDA's Accelerated Approval Program, a completed late-cycle review meeting and completed FDA inspections.
Shea said the company expects label negotiations with the agency to begin in September, while noting that Inovio would also need to confirm the design of any accelerated-approval confirmatory trial with the FDA.
A Rare HPV-Driven Disease With a Surgical Standard of Care
RRP is a rare disease caused primarily by human papillomavirus types 6 and 11 that produces wart-like papilloma growths in the respiratory tract, particularly the larynx and vocal cords, according to Shea. The condition can impair speaking, breathing and swallowing, and in some cases disease can spread through the respiratory tract and become malignant.
Shea said RRP affects an estimated 14,000 people in the United States, with about 1.8 new adult cases per 100,000 people annually. Inovio estimates at least 14,000 potential patients based on claims-database work, though Shea said the company believes the number could be higher. Treatment is concentrated among an estimated 300 to 400 laryngologists at roughly 100 U.S. treatment centers.
Current care generally relies on surgical removal of papillomas, either through laser procedures or scalpels. Because surgery does not eliminate the underlying virus, papillomas can return and patients may face repeat procedures; some patients may require hundreds of surgeries over their lifetimes, and procedures can cause permanent scarring or irreversible damage to vocal cords and respiratory tissues.
Phase I/II Data Show Durable Reductions in Surgery
INO-3107 was designed to generate an antigen-specific T-cell response against HPV types 6 and 11. The BLA is supported by the Phase I/II RRP-001 study and the RRP-002 follow-up study, which tracked patients after treatment without providing additional doses.
RRP-001 enrolled 32 patients with confirmed HPV 6- or HPV 11-associated RRP who had undergone two to eight surgeries in the preceding year; enrolled patients had required at least two surgeries to manage their disease in the previous year. Patients received four doses of INO-3107 over nine weeks after entering the study following a clinically required surgery, and any surgery needed after the initial treatment date, including during the dosing period, was counted toward the study endpoint.
According to Shea, 72% of patients achieved a 50% to 100% reduction in surgeries during the first year after treatment compared with the prior year, a proportion that rose to 86% in the second year. Twenty-eight percent of patients required no surgeries in the first 12 months after treatment, increasing to 50% in the second 12 months. The extension study produced a median follow-up period of 2.8 years.
Shea said the trial showed mainly grade 1 and grade 2 adverse events, with few systemic events. Patients have reported mild-to-moderate injection-site discomfort from the CELLECTRA (搜索) administration process that generally resolves within five to 10 minutes.
Platform Rationale and Differentiation
Inovio's platform uses plasmid DNA delivered through its proprietary CELLECTRA (搜索) device, which applies brief electrical pulses to help the DNA enter skin or muscle cells. Once inside cells, the plasmids are transcribed into mRNA and translated into proteins intended to produce sustained protein levels or generate immune responses. According to Shea, the platform is particularly suited to producing antigen-specific T-cell responses, which the company sees as important in cancer and virally mediated diseases. In the United States, CELLECTRA is regulated as part of a combination product rather than through a separate approval process, and the device already holds CE marking in the European Union.
The company said it believes INO-3107 could offer a differentiated profile because its clinical trial did not require surgeries during the dosing window to maintain minimal residual disease. Shea also said the DNA-based approach is not affected by pre-existing neutralizing antibodies and may avoid limitations associated with an immunosuppressive papilloma microenvironment.
Accelerated Approval Pathway Under Scrutiny
Shea said the FDA's file acceptance letter included a preliminary conclusion that the application might not be eligible for review under the accelerated approval pathway. Because an RRP product had previously received full approval, Inovio must demonstrate continuing unmet need and meaningful therapeutic benefit over available treatment to support accelerated approval, she said. The company subsequently submitted an assessment aid containing its clinical safety and efficacy data along with additional FDA-requested analyses.
Inovio held an informal clinical meeting with the FDA in July, where company representatives were joined by patient advocacy organizations and a physician treating RRP patients who discussed the continued unmet need and potential clinical benefit of INO-3107. Shea said the FDA did not discuss the preliminary comment in the file acceptance letter concerning accelerated approval eligibility at that time because the review was at a late stage, but indicated that feedback on the design of a confirmatory trial would be forthcoming.
The company has completed pre-licensure inspections, receiving one observation that it believes has been resolved. Inovio had previously proposed a placebo-controlled confirmatory study of about 100 patients, randomized two-to-one between active treatment and placebo. Shea said the study could include year-one and year-two readouts to confirm clinical benefit, although the FDA could request additional patients or endpoints.
Commercial Build-Out and Financial Position
As it approaches the decision date, Inovio is preparing for a potential commercial launch. Shea said the company has made key commercial preparations, including partnerships for specialty distribution, specialty pharmacy, patient support and third-party logistics, and is working with Syneos Health for contract sales and medical science liaison deployment. The company plans to use experienced field teams alongside a contract sales organization, a targeted marketing campaign and a patient-support hub, and intends to pursue access among payers and hospital systems and educate patients and caregivers about INO-3107's potential profile.
At the end of the second quarter, Inovio had $36.7 million in cash. Shea said a subsequent offering generated $18.3 million in net proceeds, extending the company's cash runway into the end of the first quarter of 2027 and through a potential INO-3107 launch if approved.
Partnered Pipeline and Earlier-Stage Programs
Beyond INO-3107, Inovio's clinical pipeline includes INO-3112 for HPV 16- and HPV 18-positive head and neck cancer (搜索), partnered with Coherus (搜索), and a glioblastoma (搜索) program partnered with Akeso. Inovio recently partnered with Akeso to evaluate INO-5401 with Akeso's bispecific checkpoint inhibitor in glioblastoma; the combination is planned for evaluation in the Dana-Farber Cancer Institute-sponsored INSIGhT trial, with the companies aiming to assess whether the regimen can improve survival and delay disease progression.
In China, Inovio partner ApolloBio (搜索) reported that its pivotal Phase III study of VGX-3100 for cervical dysplasia (搜索) met its primary endpoint. ApolloBio plans to use the data to potentially seek approval in China and related territories; if approved, Inovio could receive regulatory and sales-based milestone payments as well as royalties, Shea said.
Shea also discussed Inovio's earlier-stage dMAb and dProt platforms, which are intended to produce antibodies or therapeutic proteins directly within the body. In a Phase I trial involving SARS-CoV-2 antibodies, the company said it produced two monoclonal antibodies at potentially therapeutic levels for up to 96 weeks, with stable blood levels, no observed anti-drug antibodies and injection-site reactions as the most common side effect. The company has also presented preclinical hemophilia A (搜索) data and disclosed work in Fabry disease (搜索) and hypophosphatasia (搜索), and is seeking partners to advance those rare-disease programs and other platform opportunities.